Niraparib plus anlotinib show promise in platinum-resistant recurrent ovarian cancer

An oral combination of niraparib plus anlotinib demonstrated promising antitumour activity in patients with platinum-resistant recurrent ovarian cancer, according to results of a phase 2 study.

In the multicenter, single-arm ANNIE study, 40 patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months of last platinum-based chemotherapy, and no prior exposure to single-agent antiangiogenics and poly (ADP-ribose) polymerase (PARP) inhibitors, were included.

Patients were treated once daily with continuous oral niraparib 200 mg or 300 mg determined by baseline body weight and and anlotinib 10 mg (12 mg before protocol amendment) once daily on days 1–14 of each 21-day cycle until disease progression or intolerable toxicity. Post-baseline tumor assessments were conducted

The median follow-up was 15.4 months at the data cut-off. The intention-to-treat objective response rate (ORR) was 50%, which included 1 complete response and 19 partial responses. The median progression-free survival was 9.2 months and overall survival and 15.3 months.

Overall, 68% of patients reported drug-related, grade ≥3 treatment emergent adverse events; there were no treatment-related deaths.

Reference
Liu G, Feng Y, Li J, et al. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study. eClinicalMedicine. 2022;DOI:https://doi.org/10.1016/j.eclinm.2022.101767.